Michael Petty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Petty has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Eileen Hsich
Cleveland Clinic, OH (E.H.).
4 shared publications - Kathleen L. Grady
Northwestern University, Chicago, IL (K.L.G., T.W., D.T.P.).
4 shared publications - Margaret Murray
University of Wisconsin, Madison (M.J., M.M.).
4 shared publications - Tingqing Wu
Northwestern University, Chicago, IL (K.L.G., T.W., D.T.P.).
4 shared publications - Andrew Kao
St. Luke’s Health System, Kansas City, MO (A.K.).
3 shared publications - Brent Lampert
Ohio State University, Columbus (B.L.).
3 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (11) , e013871
Health-Related Quality of Life in Older Patients With Advanced Heart Failure From Before to 2 Years After Heart Transplantation or Long-Term Mechanical Circulatory Support: Findings From the SUSTAIN-IT Study
BACKGROUND: Health-related quality of life (HRQOL) is a key consideration among older patients with heart failure considering advanced therapies. We evaluated change in HRQOL from before to 24 months after heart transplantation (HT) or long-term mechanical circulatory support (MCS) among older (60–80 years) patients and identified factors associated with HRQOL changes. METHODS: Data for this observational study were collected from 13 US sites via patient self-reported measures (EuroQol-5-dimension-3L visual analog scale score: 0=worst–100=best imaginable health state and dimension scores; Kansas City Cardiomyopathy Questionnaire-12 overall summary score/domain scores: 0–100, higher=better health status; other measures) and a 6-minute walk test. Analyses included multivariable linear mixed-effects models. RESULTS: Of 393 enrollees, 305 underwent surgery: HT with pretransplant MCS (HT MCS)=69, HT without pretransplant MCS (HT non-MCS)=92, and long-term MCS=144. Cohort average age=66.9±4.7 years, 78% male, 83% White, 78% married/partnered, and 71% with >high school education. HT non-MCS and long-term MCS groups experienced significant improvement in average visual analog scale scores within 6 months after surgery, sustained through 24 months of follow-up; the HT MCS group EuroQol-5-dimension-3L baseline visual analog scale score was higher than those of the other 2 groups and did not improve significantly through 24 months of follow-up. The average Kansas City Cardiomyopathy Questionnaire-12 overall summary score improved in all 3 groups (baseline–6 months, sustained through 24 months). Compared with HT non-MCS, the main effect of long-term MCS showed decrements of −11.2 (−17.3 to −5.1; P P =0.002) points in EuroQol-5-dimension-3L visual analog scale. CONCLUSIONS: HT MCS improvement in HRQOL varied by measure; HT non-MCS and long-term MCS improvement occurred through 24 months, regardless of measure. Domains of HRQOL improved after these surgeries, varying by surgical strategy and postoperative time period. Long-term MCS was associated with a decrease in HRQOL across time. These findings provide important information for patients considering treatment options.
- 1 November 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (11) , e013871
Open AccessHealth-Related Quality of Life in Older Patients With Advanced Heart Failure From Before to 2 Years After Heart Transplantation or Long-Term Mechanical Circulatory Support: Findings From the SUSTAIN-IT Study
BACKGROUND: Health-related quality of life (HRQOL) is a key consideration among older patients with heart failure considering advanced therapies. We evaluated change in HRQOL from before to 24 months after heart transplantation (HT) or long-term mechanical circulatory support (MCS) among older (60–80 years) patients and identified factors associated with HRQOL changes. METHODS: Data for this observational study were collected from 13 US sites via patient self-reported measures (EuroQol-5-dimension-3L visual analog scale score: 0=worst–100=best imaginable health state and dimension scores; Kansas City Cardiomyopathy Questionnaire-12 overall summary score/domain scores: 0–100, higher=better health status; other measures) and a 6-minute walk test. Analyses included multivariable linear mixed-effects models. RESULTS: Of 393 enrollees, 305 underwent surgery: HT with pretransplant MCS (HT MCS)=69, HT without pretransplant MCS (HT non-MCS)=92, and long-term MCS=144. Cohort average age=66.9±4.7 years, 78% male, 83% White, 78% married/partnered, and 71% with >high school education. HT non-MCS and long-term MCS groups experienced significant improvement in average visual analog scale scores within 6 months after surgery, sustained through 24 months of follow-up; the HT MCS group EuroQol-5-dimension-3L baseline visual analog scale score was higher than those of the other 2 groups and did not improve significantly through 24 months of follow-up. The average Kansas City Cardiomyopathy Questionnaire-12 overall summary score improved in all 3 groups (baseline–6 months, sustained through 24 months). Compared with HT non-MCS, the main effect of long-term MCS showed decrements of −11.2 (−17.3 to −5.1; P P =0.002) points in EuroQol-5-dimension-3L visual analog scale. CONCLUSIONS: HT MCS improvement in HRQOL varied by measure; HT non-MCS and long-term MCS improvement occurred through 24 months, regardless of measure. Domains of HRQOL improved after these surgeries, varying by surgical strategy and postoperative time period. Long-term MCS was associated with a decrease in HRQOL across time. These findings provide important information for patients considering treatment options.
- 23 September 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (12) , e121-e147
Engagement of Social Support Systems in Patients Being Considered for and Following Advanced Heart and Lung Surgical Therapies: An ISHLT Expert Consensus Statement
- 23 September 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (12) , e121-e147
Engagement of Social Support Systems in Patients Being Considered for and Following Advanced Heart and Lung Surgical Therapies: An ISHLT Expert Consensus Statement
- 21 April 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (9) , 1197-1204
Caregiver burden before heart transplantation and long-term mechanical circulatory support: Findings from the sustaining quality of life of the aged: Transplant or mechanical support (SUSTAIN-IT) study
- 21 April 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (9) , 1197-1204
Caregiver burden before heart transplantation and long-term mechanical circulatory support: Findings from the sustaining quality of life of the aged: Transplant or mechanical support (SUSTAIN-IT) study
- 1 July 2016
- Published by AACN Publishing in AACN Advanced Critical Care
- Vol. 27 (3) , 291-292
When You Think You Have Seen It All: New Interventions in Transplant
- 1 July 2016
- Published by AACN Publishing in AACN Advanced Critical Care
- Vol. 27 (3) , 291-292
When You Think You Have Seen It All: New Interventions in Transplant
- 1 July 2016
- Published by AACN Publishing in AACN Advanced Critical Care
- Vol. 27 (3) , 316-323
Antibody-Mediated Rejection in Solid Organ Transplant
Within a little more than a decade, the transplant of human organs for end-stage organ disease became a reality. The early barriers to successful long-term graft and patient survival were related to the inability to effectively control the immune system such that it would not attack the donor tissue but would still recognize and destroy invading organisms and cells. As immunosuppressive therapy has been refined and proper matching of donors and recipients has been improved, hyperacute rejection has become a rare occurrence and acute rejection has been markedly controlled. However, antibody-mediated rejection remains an important impediment to increased survival of transplanted organs. This article provides readers with a broad overview of the immune system, discusses mechanisms of transplant rejection, and details prevention, detection, and treatment of antibody-mediated rejection in solid organ transplant.
- 1 July 2016
- Published by AACN Publishing in AACN Advanced Critical Care
- Vol. 27 (3) , 316-323
Antibody-Mediated Rejection in Solid Organ Transplant
Within a little more than a decade, the transplant of human organs for end-stage organ disease became a reality. The early barriers to successful long-term graft and patient survival were related to the inability to effectively control the immune system such that it would not attack the donor tissue but would still recognize and destroy invading organisms and cells. As immunosuppressive therapy has been refined and proper matching of donors and recipients has been improved, hyperacute rejection has become a rare occurrence and acute rejection has been markedly controlled. However, antibody-mediated rejection remains an important impediment to increased survival of transplanted organs. This article provides readers with a broad overview of the immune system, discusses mechanisms of transplant rejection, and details prevention, detection, and treatment of antibody-mediated rejection in solid organ transplant.